Startseite>>Signaling Pathways>> Neuroscience>> Behavioral Neuroscience>>T-5342126

T-5342126

Katalog-Nr.GC49047

A TLR4 antagonist

Products are for research use only. Not for human use. We do not sell to patients.

T-5342126 Chemische Struktur

Cas No.: 956507-49-6

Größe Preis Lagerbestand Menge
1 mg
77,00 $
Auf Lager
5 mg
328,00 $
Auf Lager
10 mg
579,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

T-5342126 is a toll-like receptor 4 (TLR4) antagonist.1 It reduces LPS-induced production of nitric oxide (NO) in RAW 264.7 cells (IC50 = 27.8 µM), as well as decreases LPS-induced IL-8, TNF-α, and IL-6 production in isolated human whole blood (IC50s = 110.5, 315.6, and 318.4 µM, respectively). T-5342126 (82 mg/kg) reduces ethanol intake and the abundance of ionized calcium-binding adapter molecule 1 (Iba1), a marker of microglial activation, in the central nucleus of the amygdala in ethanol-dependent mice.2

1.Chavez, S.A., Martinko, A.J., Lau, C., et al.Development of β-amino alcohol derivatives that inhibit toll-like receptor 4 mediated inflammatory response as potential antisepticsJ. Med. Chem.54(13)4659-4669(2011) 2.Bajo, M., Montgomery, S.E., Cates, L.N., et al.Evaluation of TLR4 inhibitor, T5342126, in modulation of ethanol-drinking behavior in alcohol-dependent miceAlcohol Alcohol.51(5)541-548(2016)

Bewertungen

Review for T-5342126

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for T-5342126

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.